JAK inhibitors are targeted drugs that block Janus kinase enzymes involved in cytokine signalling, modulating immune responses. They are clinically important for treating autoimmune diseases like rheumatoid arthritis by reducing inflammation. A key consideration is their potential to increase infection risk due to immune suppression.